JP2008532559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008532559A5 JP2008532559A5 JP2008502456A JP2008502456A JP2008532559A5 JP 2008532559 A5 JP2008532559 A5 JP 2008532559A5 JP 2008502456 A JP2008502456 A JP 2008502456A JP 2008502456 A JP2008502456 A JP 2008502456A JP 2008532559 A5 JP2008532559 A5 JP 2008532559A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- immunoglobulin
- immunoglobulin molecule
- sequence
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims 28
- 102000018358 immunoglobulin Human genes 0.000 claims 28
- 241000711549 Hepacivirus C Species 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 102000003886 Glycoproteins Human genes 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- SHFKGANKURXVMY-LCWPZEQJSA-N hcv e2 protein Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)CC1=CC=CC=C1 SHFKGANKURXVMY-LCWPZEQJSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 claims 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010076039 Polyproteins Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000054751 human RUNX1T1 Human genes 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0505697A GB0505697D0 (en) | 2005-03-19 | 2005-03-19 | Improvements in or relating to treatment and prevention of viral infection |
| US31512305A | 2005-12-23 | 2005-12-23 | |
| GB0526421A GB0526421D0 (en) | 2005-03-19 | 2005-12-23 | Improvements in or relating to treatment and prevention of viral infections |
| PCT/GB2006/000987 WO2006100449A1 (en) | 2005-03-19 | 2006-03-20 | Improvements in or relating to treatment and prevention of viral infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013121881A Division JP2013230152A (ja) | 2005-03-19 | 2013-06-10 | ウイルス感染の治療及び予防又は治療及び予防の改善 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008532559A JP2008532559A (ja) | 2008-08-21 |
| JP2008532559A5 true JP2008532559A5 (enExample) | 2009-12-24 |
Family
ID=36754660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502456A Pending JP2008532559A (ja) | 2005-03-19 | 2006-03-20 | ウイルス感染の治療及び予防又は治療及び予防の改善 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20090110685A1 (enExample) |
| EP (2) | EP2481424A1 (enExample) |
| JP (1) | JP2008532559A (enExample) |
| AU (1) | AU2006226192A1 (enExample) |
| CA (1) | CA2601400A1 (enExample) |
| WO (1) | WO2006100449A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101809033A (zh) * | 2007-07-25 | 2010-08-18 | 日本国立感染症研究所 | 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途 |
| AU2008341542B2 (en) * | 2007-12-17 | 2014-12-04 | Medical Research Council Technology | Hepatitis C virus antibodies |
| US20100104555A1 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | HCV neutralizing epitopes |
| AU2009335788A1 (en) | 2008-12-17 | 2011-07-07 | Genentech, Inc. | Hepatitis C virus combination therapy |
| CA2772613C (en) * | 2009-09-03 | 2020-03-10 | Schering Corporation | Anti-gitr antibodies |
| CN102596996B (zh) * | 2009-10-30 | 2014-06-18 | 东丽株式会社 | 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途 |
| ITFI20120122A1 (it) | 2012-06-15 | 2013-12-16 | Kedrion S P A 50 | Anticorpi monoclonali capaci di legare la proteina virale e2 loro preparazione ed uso. |
| WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
| RU2539770C1 (ru) | 2013-12-27 | 2015-01-27 | Татьяна Николаевна Власик | Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты) |
| CA2942540A1 (en) * | 2014-03-20 | 2015-09-24 | Takaji Wakita | Antibody having infection-inhibiting activity against hepatitis c virus |
| EP3189077A2 (en) * | 2014-09-05 | 2017-07-12 | Aimm Therapeutics B.V. | Hepatitis c virus specific antibody |
| GB201415714D0 (en) * | 2014-09-05 | 2014-10-22 | Medical Res Council | Antibodies and antigen binding fragments thereof |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| SU1441787A1 (ru) | 1987-04-29 | 1990-09-23 | Институт Белка Ан Ссср | Способ получени пептидов и белков в бесклеточной системе трансл ции |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| EP0446299A4 (en) | 1988-11-18 | 1992-05-13 | The Regents Of The University Of California | Method for site-specifically incorporating unnatural amino acids into proteins |
| SU1705302A1 (ru) | 1988-12-22 | 1992-01-15 | Институт Белка Ан Ссср | Способ препаративной экспрессии генов в бесклеточной системе сопр женной транскрипции/трансл ции |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| EP0593757B1 (en) | 1989-07-31 | 1997-01-15 | Institute Of Protein Research, Russian Academy Of Sciences | Method for obtaining polypeptides in a cell-free system |
| CA2067194C (en) | 1989-10-05 | 2003-03-18 | Glenn Kawasaki | Cell-free synthesis and isolation of novel genes and polypeptides |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0438310A1 (en) | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5654151A (en) | 1990-06-11 | 1997-08-05 | Nexstar Pharmaceuticals, Inc. | High affinity HIV Nucleocapsid nucleic acid ligands |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU8498091A (en) | 1990-08-02 | 1992-03-02 | Regents Of The University Of Colorado, The | Systematic polypeptide evolution by reverse translation |
| WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE69132531T2 (de) | 1990-12-06 | 2001-09-13 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Verbindungen und ihre Verwendung in einer binären Synthesestrategie |
| CA2098824A1 (en) | 1990-12-20 | 1992-06-21 | William D. Huse | Optimization of binding proteins |
| IE920562A1 (en) | 1991-02-21 | 1992-08-26 | Gilead Sciences | Aptamer specific for biomolecules and method of making |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| CA2118806A1 (en) | 1991-09-18 | 1993-04-01 | William J. Dower | Method of synthesizing diverse collections of oligomers |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| AU8124694A (en) | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
| WO1996038579A1 (en) | 1995-06-02 | 1996-12-05 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to growth factors |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| GB9603507D0 (en) * | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
| US5766686A (en) | 1996-03-01 | 1998-06-16 | North American Refractories Co. | Spray insulating coating for refractory articles |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| US5887293A (en) | 1998-01-28 | 1999-03-30 | Hennessy; Arnold | Simplified dump bucket toilet |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| WO2004041842A2 (en) * | 2002-05-16 | 2004-05-21 | The General Hospital Corporation | Epitopes of hepatitis c virus |
| TWI358301B (en) * | 2003-07-11 | 2012-02-21 | Intercell Ag | Hcv vaccines |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| AU2009335788A1 (en) * | 2008-12-17 | 2011-07-07 | Genentech, Inc. | Hepatitis C virus combination therapy |
-
2006
- 2006-03-20 WO PCT/GB2006/000987 patent/WO2006100449A1/en not_active Ceased
- 2006-03-20 AU AU2006226192A patent/AU2006226192A1/en not_active Abandoned
- 2006-03-20 JP JP2008502456A patent/JP2008532559A/ja active Pending
- 2006-03-20 EP EP11180634A patent/EP2481424A1/en not_active Withdrawn
- 2006-03-20 EP EP06726429A patent/EP1863531A1/en not_active Withdrawn
- 2006-03-20 CA CA002601400A patent/CA2601400A1/en not_active Abandoned
-
2007
- 2007-09-17 US US11/901,311 patent/US20090110685A1/en not_active Abandoned
-
2014
- 2014-03-21 US US14/222,285 patent/US20140322204A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9145454B2 (en) | Monoclonal antibodies for Ebola and Marburg viruses | |
| JP2010518854A5 (enExample) | ||
| EP3082862B1 (en) | Antibodies specific for enteroviruses that infect humans | |
| RU2012112829A (ru) | Анти-gitr-антитела | |
| CN107921285A (zh) | 多价乙型肝炎病毒抗原结合分子及其应用 | |
| JP2010502183A5 (enExample) | ||
| JP2005528914A5 (enExample) | ||
| JP2021159081A5 (enExample) | ||
| JP2008532559A5 (enExample) | ||
| RU2015151505A (ru) | Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1) | |
| JP2012518425A5 (enExample) | ||
| JP2007530551A5 (enExample) | ||
| RU2014118462A (ru) | Gp41-нейтрализующие антитела и их применение | |
| JP2011526249A5 (enExample) | ||
| JP2020505919A5 (enExample) | ||
| JPWO2020011964A5 (enExample) | ||
| JP2019507580A5 (enExample) | ||
| CN113583116A (zh) | 针对SARS-CoV-1或SARS-CoV-2的抗体及其用途 | |
| JP2020515277A5 (enExample) | ||
| JP2019505166A5 (enExample) | ||
| JP2019504615A5 (enExample) | ||
| JPWO2020011966A5 (enExample) | ||
| JP2021512159A5 (enExample) | ||
| CN113527473A (zh) | 一种全人源单克隆抗体及其应用 | |
| JPWO2020011976A5 (enExample) |